Discovering Potential COVID-19 Therapies using High Content Screening

Discovering Potential COVID-19 Therapies using High Content Screening



In this webinar, Professor Jonny Sexton discusses a pipeline, developed in the Sexton lab, for the quantitative high-throughput image-based screening of SARS-CoV-2 infection to identify potential antiviral mechanisms and allow selection of appropriate drug combinations to treat COVID-19. This webinar presents evidence that morphological profiling can robustly identify new potential therapeutics against SARS-CoV-2 infection as well as drugs that potentially worsen COVID-19 outcomes.

In this webinar, you will discover:

  • The machine learning approaches leveraged by the Sexton Lab to create an assay metric that accurately and robustly identifies features that predict antiviral efficacy and mechanism of action (MOA).
  • Several FDA-approved drugs and clinical candidates with a unique antiviral activity identified using this approach.
  • How lactoferrin inhibits viral entry and replication, enhances antiviral host cell response, and potentiates the effects of remdesivir and hydroxychloroquine.
  • How currently prescribed drugs that exacerbate viral infectivity were also identified.


Date and time

Wednesday, August 26th, 2020, 12 pm (EST) 9 am (PST) 5 pm (London)



Jonny Sexton
Assistant Professor, Internal Medicine, Division of Gastroenterology and Hepatology
Assistant Professor, College of Pharmacy, Medicinal Chemistry
Faculty Lead, Michigan Institute for Clinical & Health Research, MICHR, Drug Repurposing


Related Products & Solutions